Therapeutics News and Research

RSS

DNA Script successfully synthesizes world's first 150-nucleotide strand of DNA

DNA Script, the global leader in the development of enzymatic DNA synthesis, today announced that it has successfully synthesized the world's first 150-nucleotide strand of DNA by de novo enzymatic synthesis.

3 Oct 2018

Study highlights need for population-specific precision medicine programs in Latin America

Drug safety and effectiveness vary greatly among populations worldwide. Genetics is one of the factors that contribute to variability in drug response.

3 Oct 2018

Researchers assess effects of adding dapagliflozin to metformin or insulin in type 2 diabetes patients

Researchers used continuous glucose monitoring to assess the effects of adding dapagliflozin to a regimen of either metformin or insulin in patients with type 2 diabetes and found significant reductions in mean glucose and other glycemic factors, with greater improvements seen in patients taking metformin compared to insulin.

3 Oct 2018

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today further progress on the Company's platform efforts in extrahepatic delivery of novel siRNA conjugates, including central nervous system (CNS) and ocular delivery in rat and non-human primates (NHPs).

3 Oct 2018

Study finds disease-causing mutation in French-Canadians

A team of Canadian scientists, including researchers at the Montreal Neurological Institute and Hospital has discovered the first French-Canadian founder mutation gene linked to synucleinopathies, a group of neurodegenerative diseases that includes Parkinson's disease, dementia with Lewy-Bodies and multiple system atrophy

1 Oct 2018

New, more efficient method for generating brain stem cells in the lab

In two newly published papers, a scientific team at Case Western Reserve University School of Medicine reports on the discovery and implementation of a new, more efficient method for generating an important brain stem cell in the laboratory.

1 Oct 2018

New insights into application of drug-eluting stents during percutaneous coronary intervention

Researchers at the Thorax Centrum Twente of Medisch Spectrum Twente and the University of Twente have recently completed their fourth major study into the application of drug-eluting stents during percutaneous coronary intervention.

1 Oct 2018

$Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors$

Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors

A phase I clinical trial investigating the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid tumor malignancies, according to data presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. 30-Oct. 3.

30 Sep 2018

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

BioAxone BioSciences, Inc. announced today the receipt of a Fast-Track grant from the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, as part of the agency's Small Business Innovation Research Program.

27 Sep 2018

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

UCI School of Medicine researchers have been awarded a $3.4 million grant by the National Cancer Institute as part of the Beau Biden Cancer Moonshot initiative.

27 Sep 2018

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis.

27 Sep 2018

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.

27 Sep 2018

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

CytoSen Therapeutics, a private biopharmaceutical company accelerating innovation in Natural Killer cell therapy, today announced it has received a favorable response from the U.S. Food and Drug Administration to its pre-Investigational New Drug meeting package for the proposed Phase 2 trial of CytoSen's adoptive NK cell therapy, CSTD002-NK, for the reduction of relapse in high risk acute myeloid leukemia or myelodysplastic syndrome in patients undergoing haploidentical hematopoietic stem cell transplantation.

27 Sep 2018

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today positive topline results from the interim analysis of the ENVISION Phase 3 Study of givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria.

27 Sep 2018

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

Decibel Therapeutics and Oricula Therapeutics today announced that Decibel has obtained an exclusive, worldwide license to the development and commercialization of ORC-13661, an oral medication developed by Oricula Therapeutics for the prevention of hearing loss and balance disorders that can occur following treatment of severe infections with aminoglycoside antibiotics.

27 Sep 2018

VCU researchers to study how a gene could influence cognitive decline during chemotherapy

With the help of a $2.1 million grant, Virginia Commonwealth University School of Nursing researchers will study how a gene that regulates estrogen and neurotransmitter levels could be tied to cognitive decline in patients undergoing chemotherapy for breast and endometrial cancers.

27 Sep 2018

NIAID releases strategic plan to expand knowledge of TB by using modern tools

Tuberculosis (TB) is the leading infectious cause of death worldwide, killing roughly 1.6 million people in 2017. In the past 200 years, TB claimed the lives of more than one billion people--more deaths than from malaria, influenza, smallpox, HIV/AIDS, cholera and plague combined.

27 Sep 2018

Urine liquid biopsies could help monitor response to immunotherapy in bladder cancer patients

Scientists have shown for the first time that immune cells in the urine of bladder cancer patients accurately reflect those in the tumor environment, according to research published today (Wednesday) in the Journal of Experimental Medicine.

26 Sep 2018

Researchers discover novel targeting agents to prevent cancer metastasis

Recently, a research team led by Maurizio Pellecchia at the University of California, Riverside, discovered a way for chemotherapy drug paclitaxel to target migrating, or circulating, cancer cells, which are responsible for the development of tumor metastases.

26 Sep 2018

Alzheimer’s disease researchers makes significant breakthroughs

Researchers in Sweden and United Kingdom have made a breakthrough in Alzheimer’s disease research. They could soon be on the path to develop new drugs that could fight the disease more effectively.

26 Sep 2018

Therapeutics News and Research

DNA Script successfully synthesizes world's first 150-nucleotide strand of DNA

Study highlights need for population-specific precision medicine programs in Latin America

Researchers assess effects of adding dapagliflozin to metformin or insulin in type 2 diabetes patients

Alnylam reports further progress on broadening the therapeutic potential of RNAi

Study finds disease-causing mutation in French-Canadians

New, more efficient method for generating brain stem cells in the lab

New insights into application of drug-eluting stents during percutaneous coronary intervention

Bacterial therapy shows early clinical efficacy in patients with treatment-refractory solid tumors

Bioaxone Biosciences receives Fast-Track SBIR grant to assess potential of Rho Kinase 2 inhibitor

UCI researchers receive $3.4 million grant to study new class of cancer killing immunotherapeutics

Cidara initiates Phase 3 clinical trial to evaluate efficacy, safety of rezafungin to treat invasive candidiasis

FLX Bio treats first patient in its Phase 1/2 clinical trial of FLX475 for treating various advanced cancers

CytoSen receives favorable response from FDA to its pre-IND meeting package for CSTD002-NK

Alnylam announces positive results from Phase 3 Study of givosiran for treating acute hepatic porphyria

Decibel obtains exclusive license to commercialize ORC-13661 for preventing hearing, balance disorders

VCU researchers to study how a gene could influence cognitive decline during chemotherapy

NIAID releases strategic plan to expand knowledge of TB by using modern tools

Urine liquid biopsies could help monitor response to immunotherapy in bladder cancer patients

Researchers discover novel targeting agents to prevent cancer metastasis

Alzheimer’s disease researchers makes significant breakthroughs

Understanding the DNA Damage Response in Innate Immunity eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News